Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Cho B.C.; Hayashi H.; Lee J.S.; Lee S.H.; Danchaivijitr P.; Cheng Y.; Liu B.; Alip A.; Xiong H.; How S.H.; Chang G.C.; Yang J.C.H.; Yoshioka H.; Nahit Şendur M.A.; Prabhash K.; Azuma K.; Lee Y.G.; Lin C.C.; Matsumoto S.; Sunpaweravong P.; Xia Y.; Martinez M.; Bauml J.M.; Sethi S.; Lu S.

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

2

Issued Date

2025-06-01

Resource Type

Article

ISSN

01695002

eISSN

18728332

DOI

10.1016/j.lungcan.2025.108496

Scopus ID

2-s2.0-105003847308

Journal Title

Lung Cancer

Volume

204

Rights Holder(s)

SCOPUS

Bibliographic Citation

Lung Cancer Vol.204 (2025)

Suggested Citation

Cho B.C., Hayashi H., Lee J.S., Lee S.H., Danchaivijitr P., Cheng Y., Liu B., Alip A., Xiong H., How S.H., Chang G.C., Yang J.C.H., Yoshioka H., Nahit Şendur M.A., Prabhash K., Azuma K., Lee Y.G., Lin C.C., Matsumoto S., Sunpaweravong P., Xia Y., Martinez M., Bauml J.M., Sethi S., Lu S. Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset. Lung Cancer Vol.204 (2025). doi:10.1016/j.lungcan.2025.108496 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110000

Title

Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset

Corresponding Author(s)

Cho B.C.

Other Contributor(s)

Mahidol University

Abstract

Introduction: The incidence of epidermal growth factor receptor (EGFR) mutations is higher among Asian patients with advanced non-small cell lung cancer than the general advanced non-small cell lung cancer population. We evaluated the efficacy and safety of amivantamab in combination with lazertinib versus osimertinib in Asian participants from the phase 3 MARIPOSA study who had treatment-naïve advanced non-small cell lung cancer with common EGFR mutations. Methods: Participants were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib alone, or lazertinib alone. The primary endpoint was progression-free survival based on blinded independent central review per RECIST v1.1. Secondary endpoints included overall survival, objective response rate, duration of response, and safety. Exploratory endpoints included extracranial progression-free survival and post-progression outcomes. Results: Of 1074 randomized participants, 629 were Asian, with 250 and 251 randomized to the amivantamab-lazertinib and osimertinib arms, respectively. Among Asian participants, at a median follow-up of 22.5 months, amivantamab-lazertinib showed a 35 % reduction in the risk of disease progression or death versus osimertinib (hazard ratio, 0.65; P < 0.001). Consistent with the overall population, median progression-free survival was 27.5 and 18.3 months in the amivantamab-lazertinib and osimertinib arms, respectively. The objective response rate was 88 % for amivantamab-lazertinib versus 85 % for osimertinib. The median duration of response among confirmed responders improved by 8.6 months for amivantamab-lazertinib versus osimertinib. Favorable trends were also seen for overall survival, extracranial progression-free survival, and post-progression outcomes for amivantamab-lazertinib over osimertinib. Adverse events in Asian participants were similar to those in the overall population. Conclusions: Amivantamab-lazertinib demonstrated superior progression-free survival versus osimertinib in Asian participants, with a tolerable safety profile. These results were consistent with those in the overall population.

Keyword(s)

Biochemistry, Genetics and Molecular Biology
Medicine

URI

https://repository.li.mahidol.ac.th/handle/123456789/110000

Collections

Scopus 2025

Full item page

Send Feedback